In Week of Mar 28, 2026, Nephrocare Health Services Ltd (Hospitals/Medical Services) is outperforming Nifty 500 with +21.7% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 21, 2026
What: International revenues growing from 12% to 41% of total revenue in 3 years
Impact: +₹125 Cr revenue
“International revenues now contribute approximately 41% of the total revenue in the 9month period of financial year 26 up from 12% in financial year 23”
What: Treatment volume growth of 17.7% YoY driving operating leverage
Impact: +₹60 Cr revenue
“Treatment volume stood at 0.98 million compared to 0.84 million in Q3 FI25, a growth of 17.7%”
What: EBITDA margin expansion to 24.3% (+190 bps YoY) continuing
“EBITDA performance also remained robust driven by operating leverage and improved scale”
Earnings deceleration risks from management commentary
Trigger: Delays in Saudi market profitability
Impact: -150 bps margin impact
Management view: Adjusted EBITDA excludes expenses related to Saudi operation indicating these operations are not yet profitable
Monitor: International segment profitability
Trigger: New entrants increasing competition
Impact: -100 bps margin impact
Management view: Management emphasized 'modest price increase' strategy
Monitor: Domestic revenue per treatment growth
Key quotes from recent conference calls
“International revenues now contribute approximately 41% of the total revenue in the 9month period of financial year 26 up from 12% in financial year 23. This growth underscores our ability to leverage India platform in higher priced geographies. — Management”
“First, ramp up volumes and capacities at our existing clinic. This growth is relatively predictable as patients require scheduled weekly treatments. By expanding capacity and growing our patient base and by implementing a modest price increase, we can further strengthen our business performance. — Management”
“EBITDA performance also remained robust driven by operating leverage and improved scale on a Q3 basis. — Management”
“ROCE supported by continued discipline and capital deployment is expected to be 24.7% in FI26 improving from 18.7% in FI25. — Management”
Forward-looking targets from management for FY26
Key Milestones
• 24.7% ROCE in FI26
• Continued international expansion
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +32% | +33% | Insufficient Data |
| PAT (Net Profit) | +60% | +67% | Insufficient Data |
| OPM | 23.0% | +100 bps | Insufficient Data |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Nephrocare Health Services Ltd's latest quarterly results (Dec 2025) show
Nephrocare Health Services Ltd's profit is growing with an insufficient_data trend.
Nephrocare Health Services Ltd's revenue growth trend is insufficient_data.
Nephrocare Health Services Ltd's operating margin is insufficient_data.
Nephrocare Health Services Ltd's long-term compounding rates
Nephrocare Health Services Ltd's earnings growth is insufficient_data with insufficient_data on a sequential basis.
Nephrocare Health Services Ltd appears significantly undervalued based on our fair value analysis.
Nephrocare Health Services Ltd's current PE ratio is 66.9x.
Nephrocare Health Services Ltd's current PE is 66.9x.
Nephrocare Health Services Ltd is rated Average with a fundamental score of 49.76/100. This score is calculated from objective financial metrics
Nephrocare Health Services Ltd has a debt-to-equity ratio of N/A.
Nephrocare Health Services Ltd's return ratios over recent years
Nephrocare Health Services Ltd's operating cash flow is positive (FY2025).
Nephrocare Health Services Ltd currently does not pay a significant dividend (yield 0.00%).
Nephrocare Health Services Ltd's shareholding pattern (Dec 2025)
Nephrocare Health Services Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Nephrocare Health Services Ltd is an established outperformer with 2 weeks of consecutive Nifty 500 outperformance.
Nephrocare Health Services Ltd has 3 key growth catalysts identified from recent earnings analysis
Nephrocare Health Services Ltd has 2 key risks worth monitoring
In Q3 FY26, Nephrocare Health Services Ltd's management highlighted
Nephrocare Health Services Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why Nephrocare Health Services Ltd may be worth studying
Nephrocare Health Services Ltd investment thesis summary:
Nephrocare Health Services Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
